Not available
Quote | Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Last: | $4.11 |
---|---|
Change Percent: | -0.77% |
Open: | $3.92 |
Close: | $4.11 |
High: | $4.19 |
Low: | $3.91 |
Volume: | 1,370,068 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...
2024-03-06 07:23:30 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Ma...
Message Board Posts | Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Subject | By | Source | When |
---|---|---|---|
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed | jgrabar | investorshub | 05/31/2022 2:30:26 PM |
VNDA 12.34 - FDA Approves HETLIOZ (tasimelteon) for | RNsidersbuying | investorshub | 12/02/2020 2:26:41 PM |
Everything would be a lot better if the | XenaLives | investorshub | 07/29/2020 2:46:20 PM |
Yo, this thing is going to trade sideways | Peepson | investorshub | 07/29/2020 1:46:14 PM |
What's up? Doesn't seem to be much | XenaLives | investorshub | 07/29/2020 1:36:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire Full year 2023 revenues were $192.6 million PONVORY ® acquisition completed in Q4 2023 and transition ongoing 3 FDA PDUFA target action dates in 2024 ...
Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia PR Newswire WASHINGTON , Feb. 5, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on February 4, 2024 , i...